CD8A and non-small cell lung carcinoma: Many studies indicate that elevated percentages of CD8+PD-1+ T-cells that usually have an effector phenotype can be used as a non-invasive surrogate biomarker for immunotherapy response in solid tumors such as gastric cancer, RCC, and NSCLC [35,36,37].